Postpartum regulation of CRFR1 and CRFR2 expression in oxytocin neurons
催产素神经元 CRFR1 和 CRFR2 表达的产后调节
基本信息
- 批准号:10740490
- 负责人:
- 金额:$ 15.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAnxietyAnxiety DisordersBehaviorBehavior ControlBehavioralBirthBrainCRF receptor type 1CRF receptor type 2CaringChildCollectionCorticotropin-Releasing HormoneCorticotropin-Releasing Hormone ReceptorsDataDiscipline of NursingDiseaseEquilibriumEstrogensFOS geneFemaleGlucocorticoidsGoalsHormonesHumanHypothalamic structureMaternal BehaviorMental disordersModificationMothersMusNeurobiologyNeuronsNeuropeptidesNeurosecretory SystemsOxytocinPatternPhasePilot ProjectsPlayPostpartum DepressionPostpartum PeriodPregnancyProcessProgesteroneProlactinPsychological StressRegulationRodentRoleSignal TransductionStressSystemWomanbehavior changebiological adaptation to stressdesignexperienceexperimental studyneurobiological mechanismreceptorreceptor expressionreproductiverestraint stress
项目摘要
Project Summary
Psychological stress can profoundly impact maternal care and is associated with mental illnesses including
postpartum depression and anxiety. Approximately 900,000 women suffer from postpartum depression and
anxiety annually, resulting in devastating effects on the mother and developing child. Both oxytocin (OT) and
corticotropin releasing factor (CRF) have been implicated in stress-related behavioral changes during the
postpartum period. However, the precise mechanisms that control these changes, and the mechanisms through
which the OT and CRF systems might interact to control behavioral changes, are largely unknown. We recently
discovered that OT neurons of the mouse hypothalamus initiate expression of a receptor for CRF (CRFR1)
during the postpartum period, whereas CRFR1 is absent from OT neurons in virgin mice. Our preliminary studies
indicate the postpartum expression of CRFR1 in OT neurons modifies maternal care behaviors under conditions
of stress. Our recent findings further suggest that the other primary receptor for CRF (CRFR2) also increases in
OT neurons during the postpartum period. One critical issue that remains unknown is the factors that cause OT
neurons to express CRF receptors. Therefore, the primary goal of this proposal (Aim 1) will be to determine the
precise hormones and/or maternal experiences that induce this change. Specifically, we will treat virgin mice
with pregnancy/postpartum period specific cocktails of estrogen/progesterone, prolactin, and glucocorticoids to
determine the critical hormones that initiate CRFR1/CRFR2 expression in OT neurons. We will also determine
whether specific experiences, including nursing and maternal care, can induce CRF receptor expression in OT
neurons. Overall, experiments in Aim 1 will generate new hypotheses regarding the mechanisms through which
dramatic maternal fluctuations in hormones and maternal experiences might impact the maternal brain and
ultimately affect behaviors related to stress. In the second (smaller) aim we will perform a study to determine
how expression of CRFR2 in OT neurons changes during the postpartum period. We recently found CRFR2
levels increase within OT neurons at a single timepoint (postpartum day 7) but how CRFR2 changes across the
maternal period and whether these changes coincide temporally with alterations in CRFR1 is unknown.
Therefore, this study will allow us to determine how (a) CRFR2 levels change across the postpartum period in
mice and (b) whether CRFR2 and CRFR1 are present within the same OT neurons or in different subpopulations
of OT neurons. These findings will be critical given that CRFR1 and CRFR2 commonly have opposing roles in
regulation of stress responses and maternal behaviors. Thus, a shift in the balance of these two receptors could
have profound impacts. Overall, experiments in this R03 proposal will aid in our understanding of neurobiological
changes that occur during the maternal period and are associated human disorders including postpartum
depression, anxiety, and poor parental care.
项目概要
心理压力会深刻影响孕产妇护理,并与精神疾病相关,包括
产后抑郁和焦虑。大约90万女性患有产后抑郁症
每年都会产生焦虑,对母亲和发育中的孩子造成毁灭性影响。催产素 (OT) 和
促肾上腺皮质激素释放因子(CRF)与应激相关的行为变化有关
产后期。然而,控制这些变化的精确机制以及通过这些变化的机制
OT 和 CRF 系统可能相互作用以控制行为变化,目前尚不清楚。我们最近
发现小鼠下丘脑的 OT 神经元启动 CRF 受体 (CRFR1) 的表达
产后期间,而原始小鼠的 OT 神经元中不存在 CRFR1。我们的初步研究
表明产后 OT 神经元中 CRFR1 的表达改变了产妇护理行为
的压力。我们最近的研究结果进一步表明,CRF 的另一个主要受体 (CRFR2) 在
产后期间的 OT 神经元。导致 OT 的因素仍然是未知的一个关键问题
神经元表达 CRF 受体。因此,本提案的主要目标(目标 1)是确定
导致这种变化的精确激素和/或母亲经历。具体来说,我们将治疗处女小鼠
怀孕/产后期特定的雌激素/黄体酮、催乳素和糖皮质激素混合物
确定在 OT 神经元中启动 CRFR1/CRFR2 表达的关键激素。我们还将确定
特定的经历,包括护理和产妇护理,是否可以诱导 OT 中的 CRF 受体表达
神经元。总体而言,目标 1 中的实验将产生关于其机制的新假设
母亲荷尔蒙和母亲经历的剧烈波动可能会影响母亲的大脑和
最终影响与压力相关的行为。在第二个(较小的)目标中,我们将进行一项研究以确定
产后期间 OT 神经元中 CRFR2 的表达如何变化。我们最近发现了 CRFR2
OT 神经元内的水平在单个时间点(产后第 7 天)增加,但 CRFR2 在整个过程中如何变化
产期的变化以及这些变化是否与 CRFR1 的变化在时间上一致尚不清楚。
因此,这项研究将使我们能够确定 (a) CRFR2 水平在产后期间如何变化
小鼠以及 (b) CRFR2 和 CRFR1 是否存在于相同 OT 神经元中或不同亚群中
OT 神经元。鉴于 CRFR1 和 CRFR2 通常在
压力反应和母亲行为的调节。因此,这两种受体平衡的转变可能
产生深远的影响。总的来说,R03 提案中的实验将有助于我们理解神经生物学
产妇期间发生的变化,与人类疾病相关,包括产后
抑郁、焦虑和父母照顾不佳。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Damian Gabriel Zuloaga其他文献
Damian Gabriel Zuloaga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Damian Gabriel Zuloaga', 18)}}的其他基金
Androgen Regulation of CRF Receptor 1 as a mediator of stress responses
雄激素对 CRF 受体 1 的调节作为应激反应的调节剂
- 批准号:
10724308 - 财政年份:2023
- 资助金额:
$ 15.65万 - 项目类别:
相似海外基金
Using generative AI combined with immersive technology to treat anxiety disorders
利用生成式人工智能结合沉浸式技术治疗焦虑症
- 批准号:
10109165 - 财政年份:2024
- 资助金额:
$ 15.65万 - 项目类别:
Launchpad
Integration of stepped care for Perinatal Mood and Anxiety Disorders among Women Living with HIV in Kenya
肯尼亚艾滋病毒感染妇女围产期情绪和焦虑障碍的分级护理一体化
- 批准号:
10677075 - 财政年份:2023
- 资助金额:
$ 15.65万 - 项目类别:
Understanding the Effects of Adolescent Nicotine Exposure on Increased Risk for Mood and Anxiety Disorders: Bridging the Gap from Pre-Clinical to Clinical Investigations
了解青少年尼古丁暴露对情绪和焦虑障碍风险增加的影响:弥合临床前研究与临床研究之间的差距
- 批准号:
478121 - 财政年份:2023
- 资助金额:
$ 15.65万 - 项目类别:
Operating Grants
Addressing perinatal mood and anxiety disorders (PMADs) through a doula intervention
通过导乐干预解决围产期情绪和焦虑障碍 (PMAD)
- 批准号:
10861961 - 财政年份:2023
- 资助金额:
$ 15.65万 - 项目类别:
Evaluation of the effectiveness and implementation of online group cognitive behavioral therapy for perinatal women with anxiety disorders.
评估在线团体认知行为治疗对患有焦虑症的围产期妇女的有效性和实施情况。
- 批准号:
22KJ3164 - 财政年份:2023
- 资助金额:
$ 15.65万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Investigating the error-related negativity and the balance N1 in children with anxiety disorders
调查焦虑症儿童的错误相关消极性和平衡 N1
- 批准号:
10685283 - 财政年份:2022
- 资助金额:
$ 15.65万 - 项目类别:
RESONY: Digital therapeutic to manage anxiety disorders
RESONY:管理焦虑症的数字疗法
- 批准号:
10042996 - 财政年份:2022
- 资助金额:
$ 15.65万 - 项目类别:
Grant for R&D
Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids
通过远程医疗提供的认知行为疗法来增强苯二氮卓类药物逐渐减少的疗效,以治疗使用处方阿片类药物的焦虑症患者
- 批准号:
10705005 - 财政年份:2022
- 资助金额:
$ 15.65万 - 项目类别:
Developing an adjunctive mobile application for co-morbid substance use and anxiety disorders: comprehensive user experience testing of the Unwinding Anxiety application
开发针对共病药物使用和焦虑症的辅助移动应用程序:Unwinding Anxiety 应用程序的综合用户体验测试
- 批准号:
10597521 - 财政年份:2022
- 资助金额:
$ 15.65万 - 项目类别:
Investigating the role of neuroinflammation in environmental exposure-induced anxiety disorders
研究神经炎症在环境暴露诱发的焦虑症中的作用
- 批准号:
10573948 - 财政年份:2022
- 资助金额:
$ 15.65万 - 项目类别:














{{item.name}}会员




